Persistence of antibodies in adolescents 18−24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials

(2013) Timo Vesikari et al.   LANCET

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

(2012) María Elena Santolaya et al.   LANCET

Meningococcal serogroup B vaccines: will they live up to expectations?

(2011) Wendell D Zollinger et al.   Expert Review of Vaccines

Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults

(2011) Daniela Toneatto et al.   Human vaccines & immunotherapeutics

Review of Meningococcal Group B Vaccines

(2010) Dan M. Granoff   CLINICAL INFECTIOUS DISEASES

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

(2010) J. Donnelly et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

(2009) Carl E. Frasch et al.   VACCINE

Global epidemiology of meningococcal disease

(2009) Lee H. Harrison et al.   VACCINE

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

(2008) Martin C. J. Maiden et al.   JOURNAL OF INFECTIOUS DISEASES